Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Cardiology / Cardiovascular
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis is Recruiting • Phase…
25 Mar 2026 NCT06632457
● Recruiting Phase III Gastroenterology
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Study of Bitopertin in Participants With EPP or XLP (APOLLO) is Recruiting • Phase III • Gastroenterology • NCT06910358. The goal of this clinical…
25 Mar 2026 NCT06910358
● Recruiting Phase III Respiratory / COPD / Asthma
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis is Recruiting • Phase III • Respiratory / COPD / Asthma…
25 Mar 2026 NCT03969329
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. is Recruiting • Phase III • Cardiology / Cardiovascular • NCT03994471. Randomized, controlled, parallel groups, open-label,…
25 Mar 2026 NCT03994471
● Recruiting Phase III Oncology
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR…
25 Mar 2026 NCT07128199
● Recruiting Phase III Rheumatology
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa is Recruiting •…
25 Mar 2026 NCT06468228
● Recruiting Phase III Oncology
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma is Recruiting • Phase III • Oncology…
25 Mar 2026 NCT06980480
● Recruiting Phase III Respiratory / COPD / Asthma
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib is Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06855498.…
25 Mar 2026 NCT06855498
● Recruiting Phase III Infectious Disease
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
VE303 for Prevention of Recurrent Clostridioides Difficile Infection is Recruiting • Phase III • Infectious Disease • NCT06237452. The overall objective of the RESTORATiVE303…
25 Mar 2026 NCT06237452
● Recruiting Phase III Oncology
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b…
25 Mar 2026 NCT06937086
● Recruiting Phase III Oncology
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn’s Disease (MK-7240-008)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn’s Disease (MK-7240-008) is Recruiting • Phase…
25 Mar 2026 NCT06430801
● Recruiting Phase III Rheumatology
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn’s Disease
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With…
25 Mar 2026 NCT05995353
● Recruiting Phase III Rheumatology
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab…
25 Mar 2026 NCT06880744
● Recruiting Phase III Cardiology / Cardiovascular
High Dose Steroids in Children With Stroke
High Dose Steroids in Children With Stroke is Recruiting • Phase III • Cardiology / Cardiovascular • NCT04873583. This clinical trial deals with focal…
25 Mar 2026 NCT04873583
● Recruiting Phase III Oncology
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator’s Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator’s Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced…
25 Mar 2026 NCT07185997
● Recruiting Phase III Oncology
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC is Recruiting • Phase III • Oncology • NCT06765109. Multicenter, randomized, controlled, open-label, Phase 3…
25 Mar 2026 NCT06765109
● Recruiting Phase III Cardiology / Cardiovascular
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease is Recruiting • Phase III • Cardiology /…
25 Mar 2026 NCT05099770
● Recruiting Phase III Oncology
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight is Recruiting • Phase III • Oncology • NCT07232719. The purpose of this…
25 Mar 2026 NCT07232719
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults is Recruiting • Phase III…
25 Mar 2026 NCT07222137
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes is Recruiting • Phase III • Cardiology / Cardiovascular…
25 Mar 2026 NCT07321886
● Recruiting Phase III Oncology
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer is Recruiting…
25 Mar 2026 NCT06890598
● Recruiting Phase III Cardiology / Cardiovascular
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) is Recruiting • Phase III • Cardiology / Cardiovascular •…
25 Mar 2026 NCT07157774
● Recruiting Phase III Cardiology / Cardiovascular
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk is Recruiting • Phase III • Cardiology / Cardiovascular •…
25 Mar 2026 NCT04774159
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type…
25 Mar 2026 NCT07088068
● Recruiting Phase III Oncology
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation is…
25 Mar 2026 NCT06252649
● Recruiting Phase III Infectious Disease
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance…
25 Mar 2026 NCT05243797
● Recruiting Phase III Oncology
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is Recruiting…
25 Mar 2026 NCT06119581
● Recruiting Phase III Cardiology / Cardiovascular
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera is Recruiting • Phase III • Cardiology / Cardiovascular •…
25 Mar 2026 NCT06093672